VAN-ZOLMITRIPTAN TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

ZOLMITRIPTAN

Mevcut itibaren:

VANC PHARMACEUTICALS INC

ATC kodu:

N02CC03

INN (International Adı):

ZOLMITRIPTAN

Doz:

2.5MG

Farmasötik formu:

TABLET

Kompozisyon:

ZOLMITRIPTAN 2.5MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100

Reçete türü:

Prescription

Terapötik alanı:

SELECTIVE SEROTONIN AGONISTS

Ürün özeti:

Active ingredient group (AIG) number: 0134381001; AHFS:

Yetkilendirme durumu:

CANCELLED PRE MARKET

Yetkilendirme tarihi:

2019-07-31

Ürün özellikleri

Page | 1
PRODUCT MONOGRAPH
PR
VAN-ZOLMITRIPTAN
ZOLMITRIPTAN TABLETS
2.5 MG
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Date of Preparation: March 25, 2015
Unit-210, 2639 Viking Way
Richmond, BC V6V 3B7
www.vancpharm.com
Control# 182335
Page | 2
TABLE OF CONTENTS
PRODUCT MONOGRAPH
......................................................................................................
1
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
17
DOSAGE AND ADMINISTRATION
................................................................................
19
OVERDOSAGE
..................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 20
STORAGE AND STABILITY
............................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATIO